AIM
AIM ImmunoTech Inc. AMEX Listed Nov 2, 1995$0.25
+0.00%
vs $0.25
Mkt Cap $404.7K
52w Low $0.22
1.2% of range
52w High $2.71
50d MA $0.28
200d MA $0.75
P/E (TTM)
-0.1x
EV/EBITDA
—
P/B
—
Debt/Equity
-0.5x
ROE
142.7%
P/FCF
-0.0x
RSI (14)
37.20
ATR (14)
$0.02
Beta
1.36
50d MA
$0.28
200d MA
$0.75
Avg Volume
1.2M
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
2117 SW Highway 484 · Ocala, FL 34473 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | AMC | -0.17 | -0.43 | -152.9% | 0.29 | -7.5% | -7.8% | -3.2% | +0.9% | +0.6% | -15.0% | — |
| May 15, 2026 | AMC | -1.08 | -0.69 | +36.1% | 0.25 | +8.9% | +61.3% | +0.7% | -38.4% | -3.8% | -2.6% | — |
| Mar 27, 2026 | AMC | -0.94 | -0.44 | +53.2% | 0.70 | +2.0% | -21.3% | +6.2% | -6.0% | +8.2% | -0.7% | — |
| Nov 17, 2025 | AMC | -0.97 | -1.57 | -61.0% | 1.44 | +0.7% | -7.6% | +0.0% | -2.3% | +5.4% | -1.5% | — |
| Aug 14, 2025 | AMC | -8.00 | -3.68 | +54.0% | 2.42 | +0.0% | +2.9% | -10.8% | +6.3% | -0.8% | +8.1% | — |
| May 15, 2025 | AMC | -8.00 | -5.00 | +37.5% | 8.47 | +0.0% | -11.1% | +12.5% | +0.0% | +0.0% | +0.0% | — |
| Mar 27, 2025 | AMC | -9.00 | -10.00 | -11.1% | 12.23 | +0.0% | -7.7% | +0.0% | +8.3% | -7.7% | +0.0% | — |
| Nov 14, 2024 | AMC | -10.00 | -6.00 | +40.0% | 23.52 | -4.0% | -12.0% | +4.5% | -21.7% | +11.1% | +5.0% | — |
| Aug 14, 2024 | AMC | -0.12 | -3.00 | -2400.0% | 25.40 | +0.0% | +7.4% | +3.5% | +3.3% | +16.1% | +8.3% | — |
| May 16, 2024 | AMC | -0.11 | -12.00 | -9999.0% | 36.69 | +7.7% | +2.6% | +2.5% | +0.0% | +0.0% | -2.4% | — |
| Mar 29, 2024 | AMC | -0.15 | -26.00 | -9999.0% | — | — | — | — | — | — | — | — |
| Nov 14, 2023 | AMC | -0.11 | -16.00 | -9999.0% | 42.34 | +0.0% | +4.4% | +0.0% | -4.3% | -8.9% | -2.4% | — |
| Aug 15, 2023 | AMC | -0.11 | -10.00 | -8990.9% | 60.21 | -3.1% | -3.1% | +0.0% | +0.0% | -1.6% | +9.8% | — |
| May 12, 2023 | AMC | -0.11 | -8.00 | -7172.7% | 41.40 | +0.0% | -2.3% | -2.3% | +19.0% | +0.0% | -6.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 10 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.52 | $0.53 | +2.3% | +1.2% | +1.3% | +9.0% | -5.7% | +3.0% |
| Dec 8 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.38 | $1.39 | +0.7% | +10.1% | -2.0% | -2.7% | +0.0% | -5.5% |
| Oct 3 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.49 | $2.55 | +2.4% | -0.4% | +1.6% | -2.0% | -2.0% | +1.2% |
| Dec 10 | Ascendiant Capital | Maintains | Buy → Buy | — | $20.70 | $21.64 | +4.5% | +0.0% | -4.5% | +0.0% | +4.8% | -4.5% |
| Oct 22 | Maxim Group | Maintains | Buy → Buy | — | $24.46 | $25.40 | +3.8% | +3.8% | -3.7% | +0.0% | +3.8% | +0.0% |
| Sep 3 | Ascendiant Capital | Maintains | Buy → Buy | — | $31.99 | $31.99 | +0.0% | +2.9% | -2.9% | -2.9% | +0.0% | +0.0% |
| Oct 10 | Maxim Group | Upgrade | Hold → Buy | — | $53.63 | $64.92 | +21.1% | +5.3% | -1.7% | -1.7% | -5.2% | +7.3% |
| Aug 22 | Maxim Group | Downgrade | Buy → Hold | — | $180.63 | $180.63 | +0.0% | +0.0% | +0.5% | -3.1% | +0.0% | -0.5% |
| Jun 14 | Maxim Group | Maintains | Buy → Buy | — | $503.31 | $518.36 | +3.0% | -5.0% | -5.5% | -11.0% | -5.9% | +0.2% |
| Jan 21 | Chardan Capital | Maintains | Buy → Buy | — | $20365.75 | $24836.29 | +22.0% | +9.8% | +2.2% | +19.6% | -7.3% | -5.9% |
No insider trades available.
8-K · 7.01
! Medium
AIM ImmunoTech Inc. -- 8-K 7.01: Regulation FD Disclosure
Aug 11
8-K · 2.02
!! High
AIM ImmunoTech Inc. -- 8-K 2.02: Earnings Results
Aug 10
8-K · 1.02
!! High
AIM ImmunoTech Inc. -- 8-K 1.02: Material Agreement Terminated
Aug 5
8-K
AIM ImmunoTech Inc. -- 8-K Filing
Jul 16
8-K · 8.01
!! High
AIM ImmunoTech Inc. -- 8-K 8.01: Material Event / Announcement
AIM ImmunoTech regained compliance with all NYSE American continued listing standards, eliminating immediate delisting risk and improving its exchange standing.
Jun 15
8-K · 1.01
! Medium
AIM ImmunoTech Inc. -- 8-K 1.01: Equity Issuance
Jun 11
8-K · 5.03
! Medium
AIM ImmunoTech Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Jun 10
8-K · 7.01
! Medium
AIM ImmunoTech Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 4
8-K · 8.01
!! High
AIM ImmunoTech Inc. -- 8-K 8.01: Material Event / Announcement
May 21
8-K · 1.01
! Medium
AIM ImmunoTech Inc. -- 8-K 1.01: Financing / Debt Agreement
May 19
8-K · 7.01
! Medium
AIM ImmunoTech Inc. -- 8-K 7.01: Regulation FD Disclosure
May 14
8-K · 1.01
!! High
AIM ImmunoTech Inc. -- 8-K 1.01: Material Agreement
AIM ImmunoTech signed an agreement with Ladenburg Thalmann, likely for underwriting or financial advisory services, potentially supporting future capital-raising activities or corporate transactions.
May 8
8-K · 1.01
!! High
Unknown — 8-K 1.01: Distribution Agreement
AIM can raise up to $3.0 million through Maxim Group LLC, providing capital flexibility without debt while diluting existing shareholders unless proceeds fund accretive growth.
Apr 10
8-K · 8.01
!! High
AIM ImmunoTech Inc. -- 8-K 8.01: Material Event / Announcement
AIM ImmunoTech completed its rights offering, allowing existing shareholders to purchase additional shares at a predetermined price to raise capital.
Mar 6
8-K · 8.01
!! High
AIM ImmunoTech Inc. -- 8-K 8.01: Material Event / Announcement
AIM ImmunoTech is conducting a Phase I/II trial combining Durvalumab and Rintatolimod for pancreatic cancer, with interim results potentially validating the company's immunotherapy approach for this difficult-to-treat indication.
Feb 5
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Avantis International Equity ETF | 5,405 | $12K | Feb 2026 |
| 2 | Avantis Responsible International Equity ETF | 1,856 | $4K | Feb 2026 |
Valuation
Market Cap
$405K
Enterprise Value
$339K
P/E (TTM)
-0.07x
Forward P/E
—
PEG Ratio
0.01x
P/B
—
P/S
4.26x
P/FCF
-0.04x
EV/EBITDA
—
Shares Out
1.6M
Financials (TTM)
Revenue
$95K
Net Income
-$14.3M
EBITDA
-$12.9M
Free Cash Flow
-$11.0M
Op Cash Flow
-$11.0M
EPS Basic
$-8.62
EPS Diluted
$-3.84
EPS Forward
$-1.47
Gross Margin
-125.3%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$5.8M
Total Liab.
$15.6M
Total Equity
-$9.8M
Cash
$993K
LT Debt
$927K
Book Value/Sh
$-6.04
Debt/Equity
-0.50x
Current Ratio
0.53
Quick Ratio
0.53
Returns & Growth
ROE
142.7%
ROA
-241.4%
ROIC
-313.6%
Rev Growth YoY
-48.2%
EPS Growth YoY
+23.2%
Price Returns
2W
-2.7%
1M
+0.0%
3M
-37.7%
6M
-72.5%
12M
-89.4%
Technicals
52W High
$2.71
52W Low
$0.22
50d MA
$0.28
200d MA
$0.75
RSI (14)
37.20
ATR (14)
$0.02
Beta
1.36
Avg Volume
1.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 4:51pm
· Source: financialmodelingprep.com